European drugmakers announced a trio of deals around a billion dollars each to buy U.S.-listed biopharmas at hefty premiums
European drugmakers on Monday announced a trio of deals around a billion dollars each to buy U.S.-listed biopharmas at hefty premiums.
Anglo-Swedish AstraZeneca AZN UK:AZN said it’s paying up to $1.8 billion for CinCor Pharma, a maker of a blood pressure medication. It’s offering $26 per share in cash, plus as much as another $10 per share if it’s able to make a Food and Drug Administration submission for a product based on baxdrostat drug in development for hypertension as well as chronic kidney disease.
CinCor... European drugmakers on Monday announced a trio of deals around a billion dollars each to buy U.S.-listed biopharmas at hefty premiums. Anglo-Swedish AstraZeneca AZN AZN said it’s paying up to $1.8 billion for CinCor Pharma, a maker of a blood pressure medication. It’s offering $26 per share in cash, plus as much as another $10 per share if it’s able to make a Food and Drug Administration submission for a product based on baxdrostat drug in development for hypertension as well as chronic kidney disease.Another deal saw Italy’s Chisi Farmaceutici agree to pay up to $1.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
European Journalist Org Concerned by Ukraine Media Censorship LawThe European Federation of Journalists (EFJ), Europe’s largest journalist association, has expressed concern about a new Ukrainian law that could arbitrarily censor media in the country.
Leer más »
100 Best Selling BEVs in 10 European CountriesBy Maarten Vinkhuyzen and Zach Shahan Because we never have enough statistics, here's another list of top selling electric vehicles — this one showing the 100 best selling BEVs in 10 European countries (combined) in
Leer más »
European markets set for positive open, buoyed by China reopeningEuropean markets are heading for a positive open at the start of the new trading week, with market sentiment buoyed by a further reopening of China's economy.
Leer más »
AstraZeneca PLC Will Buy CinCor for Cardiorenal AssetBy Joe Hoppe AstraZeneca PLC said Monday that it has agreed to buy CinCor Pharma, Inc., acquiring global rights to the latter's baxdrostat cardiorenal drug...
Leer más »
AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln dealAstraZeneca said on Monday it will buy U.S.-based clinical-stage biopharmaceutical firm CinCor Pharma Inc in a deal valued at about $1.8 billion to strengthen its pipeline of heart and kidney drugs.
Leer más »
European shares rise on China reopening, rate hike optimismEuropean shares rose on Monday, extending the year's upbeat start to a second week, as China reopened its borders overnight and U.S. and European data soothed nerves about aggressive tightening by major global central banks.
Leer más »